Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) remains a significant global health challenge.
• Dipeptidyl peptidase-4 (DPP-4) inhibitors are a crucial class of antidiabetic drugs.
• Developing novel DPP-4 inhibitors with improved efficacy and safety profiles is essential.

Purpose of the Study:

• To review various scaffolds for designing novel dipeptidyl peptidase-4 (DPP-4) inhibitors.
• To explore structure-activity relationships and synthesis strategies for DPP-4 inhibitors.
• To identify promising scaffolds and substitutions for future T2DM therapeutic development.

Main Methods:

• Literature review of diverse DPP-4 inhibitory scaffolds.
• Molecular docking studies of existing DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin) using Maestro 12.5.
• Analysis of structure-activity relationships based on IC50 values.
• Examination of synthesis schemes for commercially available DPP-4 inhibitors.

Main Results:

• Identified several scaffolds with high DPP-4 inhibition activity, including pyrazolopyrimidine, tetrahydro pyridopyrimidine, uracil-based, triazole-based, fluorophenyl-based, glycinamide, glycolamide, β-carbonyl 1,2,4-triazole, and quinazoline motifs.
• Demonstrated that halogen substitutions (fluorine, chlorine, bromine) can enhance compound potential.
• Elucidated interactions between existing drugs and DPP-4 active sites through docking studies.

Conclusions:

• Various heterocyclic scaffolds are effective for developing DPP-4 inhibitors.
• Halogenated scaffolds represent a promising avenue for future DPP-4 inhibitor research.
• Understanding molecular interactions aids in the rational design of novel antidiabetic agents.